Jiarui Feng

Jiarui Feng

Auto-generated profile, based on publicly available information

Jiarui Feng

Washington University in St. Louis

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2024
Verified
Conference Paper
Open access
HLHao Liu
Hao Liu
JFJiarui Feng
Jiarui Feng
LKLecheng Kong
Lecheng Kong
DTDacheng Tao
Dacheng Tao
YCYixin Chen
Yixin Chen
MZMuhan Zhang
Muhan Zhang
Graph Neural Networks (GNNs) have become popular tools for Graph Representation Learning (GRL). One fundamental problem is few-shot node classification. Most existing methods follow the meta learning paradigm, showing the ability of fast generalization to few-shot tasks. However, recent works indicate that graph contrastive learning combined with fine-tuning can significantly outperform meta learning methods. Despite the empirical success, there is limited understanding of the reasons behind it. In our study, we first identify two crucial advantages of contrastive learning over meta learning, including (1) the comprehensive utilization of graph nodes and (2) the power of graph augmentations. To integrate the strength of both contrastive learning and meta learning on the few-shot node classification tasks, we introduce a new paradigm-Contrastive Few-Shot Node Classification (COLA). Specifically, COLA identifies semantically similar nodes only from augmented graphs, enabling the construction of meta-tasks without label information. Therefore, COLA can incorporate all nodes to construct meta-tasks, reducing the risk of overfitting. Through extensive experiments, we validate the necessity of each component in our design and demonstrate that COLA achieves new state-of-the-art on all tasks.

13 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
HZHeming Zhang
Heming Zhang
JFJiarui Feng
Jiarui Feng
AZAmanda Zeng
Amanda Zeng
PPPhilip R Payne
Philip R Payne
FLFuhai Li
Fuhai Li
Drug combinations targeting multiple targets/pathways are believed to be able to reduce drug resistance. Computational models are essential for novel drug combination discovery. In this study, we proposed a new simplified deep learning model, DeepSignalingSynergy , for drug combination prediction. Compared with existing models that use a large number of chemical-structure and genomics features in densely connected layers, we built the model on a small set of cancer signaling pathways, which can mimic the integration of multi-omics data and drug target/mechanism in a more biological meaningful and explainable manner. The evaluation results of the model using the NCI ALMANAC drug combination screening data indicated the feasibility of drug combination prediction using a small set of signaling pathways. Interestingly, the model analysis suggested the importance of heterogeneity of the 46 signaling pathways, which indicates that some new signaling pathways should be targeted to discover novel synergistic drug combinations.

9 February 2023
Verified
Book Chapter
Closed access
PDF file
ASAnindya Sarkar
Anindya Sarkar
JFJiarui Feng
Jiarui Feng
YVYevgeniy Vorobeychik
Yevgeniy Vorobeychik
CGChristopher Gill
Christopher Gill
NZNing Zhang
Ning Zhang

15 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JFJiarui Feng
Jiarui Feng
MPMichael Province
Michael Province
GLGuangfu Li
Guangfu Li
PPPhilip R.O. Payne
Philip R.O. Payne
YCYixin Chen
Yixin Chen
FLFuhai Li
Fuhai Li
Recently, large-scale scRNA-seq datasets have been generated to understand the complex and poorly understood signaling mechanisms within microenvironment of Alzheimer’s Disease (AD), which are critical for identifying novel therapeutic targets and precision medicine. Though a set of targets have been identified, however, it remains a challenging to infer the core intra- and inter-multi-cell signaling communication networks using the scRNA-seq data, considering the complex and highly interactive background signaling network. Herein, we introduced a novel graph transformer model, PathFinder, to infer multi-cell intra- and inter-cellular signaling pathways and signaling communications among multi-cell types. Compared with existing models, the novel and unique design of PathFinder is based on the divide-and-conquer strategy, which divides the complex signaling networks into signaling paths, and then score and rank them using a novel graph transformer architecture to infer the intra- and inter-cell signaling communications. We evaluated PathFinder using scRNA-seq data of APOE4-genotype specific AD mice models and identified novel APOE4 altered intra- and inter-cell interaction networks among neurons, astrocytes, and microglia. PathFinder is a general signaling network inference model and can be applied to other omics data-driven signaling network inference.

6 January 2023 in arXiv
Verified
Preprint
Open access
PDF file
JFJiarui Feng
Jiarui Feng
YCYixin Chen
Yixin Chen
FLFuhai Li
Fuhai Li
ASAnindya Sarkar
Anindya Sarkar
MZMuhan Zhang
Muhan Zhang
The most popular design paradigm for Graph Neural Networks (GNNs) is 1-hop message passing -- aggregating information from 1-hop neighbors repeatedly. However, the expressive power of 1-hop message passing is bounded by the Weisfeiler-Lehman (1-WL) test. Recently, researchers extended 1-hop message passing to K-hop message passing by aggregating information from K-hop neighbors of nodes simultaneously. However, there is no work on analyzing the expressive power of K-hop message passing. In this work, we theoretically characterize the expressive power of K-hop message passing. Specifically, we first formally differentiate two different kernels of K-hop message passing which are often misused in previous works. We then characterize the expressive power of K-hop message passing by showing that it is more powerful than 1-WL and can distinguish almost all regular graphs. Despite the higher expressive power, we show that K-hop message passing still cannot distinguish some simple regular graphs and its expressive power is bounded by 3-WL. To further enhance its expressive power, we introduce a KP-GNN framework, which improves K-hop message passing by leveraging the peripheral subgraph information in each hop. We show that KP-GNN can distinguish many distance regular graphs which could not be distinguished by previous distance encoding or 3-WL methods. Experimental results verify the expressive power and effectiveness of KP-GNN. KP-GNN achieves competitive results across all benchmark datasets.

14 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JFJiarui Feng
Jiarui Feng
HZHeming Zhang
Heming Zhang
FLFuhai Li
Fuhai Li
Survival analysis and prediction are important in cancer studies. In addition to the Cox proportional hazards model, recently deep learning models have been proposed to integrate the multi-omics data for survival prediction. Cancer signaling pathways are important and interpretable concepts that define the signaling cascades regulating cancer development and drug resistance. Thus, it is interesting and important to investigate the relevance to patients’ survival of individual signaling pathways. In this exploratory study, we propose to investigate the relevance and difference of a small set of core cancer signaling pathways in the survival analysis of cancer patients. Specifically, we built a biologically meaningful and simplified deep neural network, DeepSigSurvNet, for survival prediction. In the model, the gene expression and copy number data of 1648 genes from 46 major signaling pathways are used. We applied the model on 4 types of cancer and investigated the relevance and difference of the 46 signaling pathways among the 4 types of cancer. Interestingly, the interpretable analysis identified the distinct patterns of these signaling pathways, which are helpful to understand the relevance of the signaling pathways in terms of their association with cancer survival time. These highly relevant signaling pathways can be novel targets, combined with other essential signaling pathways inhibitors, for drug and drug combination prediction to improve cancer patients’ survival time.